Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
Trial details
- Registry ID
- NCT06615557
- Drugs studied
- Fasedienol Nasal Spray
TrialRedline tracks 7 clinical trials sponsored by VistaGen Therapeutics, Inc.: 5 Phase 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)NCT06615557 | Fasedienol Nasal Spray | Completed | 2026-04-21Actual |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)NCT06358651 | Fasedienol Nasal Spray | Completed | 2025-10-31Actual |
| PH94B Nasal Spray for Anxiety Induced by a Public Speaking ChallengeNCT04754802 | PH94B Nasal Spray | Completed | 2022-06-22Actual |
| Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)NCT05030350 | PH94B | Terminated | 2022-09-23Actual |
| PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2NCT05011396 | PH94B Nasal Spray | Terminated | 2022-08-16Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety DisorderNCT06809179 | Fasedienol Nasal Spray - Fasedienol Nasal Spray | Completed | 2026-06-12Actual |
| PH94B in the Treatment of Adjustment Disorder With AnxietyNCT04404192 | PH94B | Completed | 2022-12-14Actual |
Names as written in the registry records.
Before: Estimated. After: Actual.
Before: 60 participants (planned). After: 61 participants (actual).
Before: Estimated. After: Actual.
Before: Apr 2026. After: 12 Jun 2026.
Before: Recruiting. After: Completed.
NCT06615557 · VistaGen Therapeutics, Inc.
Before: Active not recruiting. After: Completed.
NCT06358651 · VistaGen Therapeutics, Inc.
Before: Active not recruiting. After: Completed.
NCT06615557 · VistaGen Therapeutics, Inc.
Before: Estimated. After: Actual.
Before: 236 participants (planned). After: 238 participants (actual).
Before: Estimated. After: Actual.
Before: Apr 2026. After: 21 Apr 2026.
Before: Recruiting. After: Active not recruiting.
NCT04404192 · VistaGen Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Hamilton Anxiety Scale. After: Measure: Hamilton Anxiety Scale (HAM-A) Score.
NCT06358651 · VistaGen Therapeutics, Inc.
Before: Estimated. After: Actual.
Before: 236 participants (planned). After: 238 participants (actual).
Before: Estimated. After: Actual.
Before: Oct 2025. After: 31 Oct 2025.
Before: Recruiting. After: Active not recruiting.
NCT05011396 · VistaGen Therapeutics, Inc.
Before: 141 participants (actual). After: 228 participants (actual).